Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. Table A and B, in vitro synergy of romidepsin and pralatrexate.

Slides:

Advertisements

Similar presentations

(Journal of Biomedical and Clinical Sciences)

Advertisements

Supplemental Digital Content 4

by Javier Navarro-Antolín, Konstantin L

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

Caspase-1 from myeloid cells induces tumor proliferation via MyD88 oncogenic signaling. Caspase-1 from myeloid cells induces tumor proliferation via MyD88.

Microarray analysis of phospho-Twist1–responsive genes.

Downregulated ABCG2 Enhances Sensitivity to Topoisomerase I Inhibitor in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Non-small.

Yuchun Luo, Lixia Z. Ellis, Katiuscia Dallaglio, Moe Takeda, William A

Predicting drug sensitivity and resistance

High correlation of expression changes of NMD-regulated genes identified by both the pSILAC screen and previously reported global RNA screens after UPF1.

An siRNA screen identifies BER pathway members as sensitizers to temozolomide (TMZ) in pediatric GBM. A and B, SJG2 and KNS42 cells were transfected with.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

Treatment with MI-773 causes changes in p53 status.

Mechanism of piperlongumine induced Sp downregulation.

RNA abundance correlates with fitness.

MMAE resistance and intracellular accumulation.

LSD1, a histone demethylase, is required for the assembly of the Notch repressor complex. LSD1, a histone demethylase, is required for the assembly of.

Bcl-XL upregulates the expression of genes characteristic to midbrain and hindbrain fates during in vitro differentiation of ES cells. Bcl-XL upregulates.

VP16-E2 is a more potent transcriptional activator than Gal4-VP16.

Induction of CDKN1A (□), MDM2 (◊), and GADD45A (○) in ML-1 cells by 50 cGy X-rays delivered at 0.28 cGy/min. Induction of CDKN1A (□), MDM2 (◊), and GADD45A.

Synergistic effect of CNP and doxorubicin (DOX) on thiol oxidation.

Epigenetic regulation of p16INK4a in human gastric cancer.

Protein expression profile in a dasatinib-resistant cell line.

CCG regulates cellular localization and blocks target gene expression of MRTF. A, SK-Mel-147 cells were cotransfected with RhoC and the SRE.L reporter.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.

Radiosensitization by combined Wee1 and PARP inhibition.

Confirmation of candidates from WT1 binding site screen.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

DAC treatment activates expression of immunoregulatory genes.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Peptide dose-response curves were done to estimate the avidity of these HTL for peptide TARP1-14 (A) and TARP14-27 (B-E) using autologous PBMCs and dendritic.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

IAA inhibits PI3K, MKK4, and MKK7 kinase activities by directly binding in an ATP-competitive manner. IAA inhibits PI3K, MKK4, and MKK7 kinase activities.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Tipifarnib and bortezomib are synergistic in cytotoxicity assays

Expression of S100A11 in bulk pancreatic tissues (pancreatic cancer, n = 22; IPMN, n = 18; nonneoplastic pancreas, n = 22). Expression of S100A11 in bulk.

In vitro time course assays for four renal selective compounds.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Reduced klotho expression in pancreatic cancer.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells. Effect of siltuximab on paclitaxel sensitivity in ovarian cancer.

RUNX3 depletion induces cellular senescence and inflammatory cytokine expression in cells undergoing TGFβ-mediated EMT. A, Cells were transfected with.

Tivantinib does not inhibit MET function.

Tivantinib behaves as an antimitotic agent.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

Osteoactivin expression is required for the invasive phenotype of in vivo selected bone metastatic 4T1 breast cancer cells. Osteoactivin expression is.

Free interstitial drug as a function of the initial load of soluble drug, ci0 and the intracellular binding capacity, bc,max. Free interstitial drug as.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Growth inhibition of HNSCC cells in vitro with curcumin

The effects of AZD1775 and olaparib on DNA damage response signaling.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Interaction of NHEJ and HR pathways in PCO cultures.

Validation of NAA's cancer specificity in lung cancer.

A, left: LNCaP cells were cultured in media containing complete serum, treated for 24 hours with either ethanol control (0.01%), ABT888 (2.5 mmol/L), or.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

Hcy decreases VEGFR1/2 and Angs (Ang1, Ang2) gene transcription

ABT-888 sensitizes multiple ovarian cancer cell lines but not normal cells to FdUrd. ABT-888 sensitizes multiple ovarian cancer cell lines but not normal.

Expression of chemokine receptors in A-498 cell line.

IL-1β expression is increased in MM cell lines by the co-culture with platelets in vitro. IL-1β expression is increased in MM cell lines by the co-culture.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Presentation transcript:

Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. HTS procedure was used to explore the combination of romidepsin and pralatrexate in vitro in TCL cell lines H9 and HH. Romidepsin was dosed at 0.002 μmol/L and pralatrexate was dosed in a range of 0.02 to 1 μmol/L after testing 10 different concentrations of each drug. Based on the excess over bliss model, values >10 were suggestive of synergistic effect of combination versus additive. Each value reported is the average of at least 3 independent experiments run in triplicate. H9 cell line demonstrated synergy at 48 hours, whereas HH exhibited synergistic effect at 72 hours as exhibited in Tables A and B, respectively. *There was no observed difference of the combination at 24 hours compared with any of the single-drug treatments. C, Heatmap showing quantitative PCR analysis of RNA expression following romidepsin and pralatrexate. Response of genes with potential impact on pralatrexate sensitivity or resistance is shown. Positive controls, B1 [ABCB1 (ATP-binding cassette, sub-family G, member 1) or MDR1 (multi-drug resistance gene)], FOS (Proto-oncogene c-FOS), and p21, often found upregulated in response to romidepsin (Romi), are shown for each cell line. Genes with potential impact on pralatrexate intracellular retention or resistance: ABCG2 (ATP-binding cassette, sub-family G, member 2), GGH, FPG, DHFR, and RFC. Scale is shown next to the figure ranging from X to X-fold induction. Salvia Jain et al. Clin Cancer Res 2015;21:2096-2106 ©2015 by American Association for Cancer Research